Göran Rådegran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Göran Rådegran has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Abdulla Ahmed
Department of Clinical Sciences Lund, The Section for Cardiology Lund University Lund Sweden
13 shared publications - Salaheldin Ahmed
Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden
12 shared publications - Habib Bouzina
Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden
7 shared publications - Barbro Kjellström
Clinical Physiology, Department of Clinical Sciences Lund, Lund University , Entrégatan 7, 222 42 Lund
6 shared publications - Jakob Lundgren
Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden
5 shared publications - Clara Hjalmarsson
Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden
4 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (10) , e70705
Development in Left Ventricular Mass After Early and Late Conversion From Calcineurin Inhibitors to Everolimus in Heart Transplant Recipients—Results From Two Randomized Controlled Trials
Left ventricular hypertrophy in heart transplant recipients has been attributed to the use of calcineurin inhibitors. We assessed left ventricular mass across treatment arms in 83 heart transplant recipients in the Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE), and in 75 maintenance recipients in the Nordic Certican Trial in Heart and Lung Transplantation (NOCTET). In SCHEDULE, we randomized participants to treatment with calcineurin inhibitors or replacement with everolimus within 7–11 weeks after transplant. In NOCTET, participants were randomized to treatment with calcineurin inhibitors or a combination of low dose calcineurin inhibitors and everolimus. We followed patients with echocardiography for 3 years in the SCHEDULE trial and for 5 years in NOCTET. In SCHEDULE, left ventricular mass diminished with time, particularly across the first year of follow‐up (everolimus arm: −10 ± 18 g/m 2 , cyclosporine arm: −9 ± 13 g/m 2 ). However, there was no between‐group difference in this development ( p = 0.91). In NOCTET, there was no significant change in LVM over time and no between‐group difference in the change ( p = 0.27). In conclusion, t he replacement of calcineurin inhibitors with everolimus or a reduction in the calcineurin inhibitor dose did not mitigate left ventricular hypertrophy after heart transplantation. Trial Registration: SCHEDULE—ClinicalTrials.gov Identifier: NCT01266148; NOCTET—ClinicalTrials.gov Identifier: NCT00377962
- 9 October 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (10) , e70705
Open AccessDevelopment in Left Ventricular Mass After Early and Late Conversion From Calcineurin Inhibitors to Everolimus in Heart Transplant Recipients—Results From Two Randomized Controlled Trials
Left ventricular hypertrophy in heart transplant recipients has been attributed to the use of calcineurin inhibitors. We assessed left ventricular mass across treatment arms in 83 heart transplant recipients in the Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE), and in 75 maintenance recipients in the Nordic Certican Trial in Heart and Lung Transplantation (NOCTET). In SCHEDULE, we randomized participants to treatment with calcineurin inhibitors or replacement with everolimus within 7–11 weeks after transplant. In NOCTET, participants were randomized to treatment with calcineurin inhibitors or a combination of low dose calcineurin inhibitors and everolimus. We followed patients with echocardiography for 3 years in the SCHEDULE trial and for 5 years in NOCTET. In SCHEDULE, left ventricular mass diminished with time, particularly across the first year of follow‐up (everolimus arm: −10 ± 18 g/m 2 , cyclosporine arm: −9 ± 13 g/m 2 ). However, there was no between‐group difference in this development ( p = 0.91). In NOCTET, there was no significant change in LVM over time and no between‐group difference in the change ( p = 0.27). In conclusion, t he replacement of calcineurin inhibitors with everolimus or a reduction in the calcineurin inhibitor dose did not mitigate left ventricular hypertrophy after heart transplantation. Trial Registration: SCHEDULE—ClinicalTrials.gov Identifier: NCT01266148; NOCTET—ClinicalTrials.gov Identifier: NCT00377962
- Open Access
- 30 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (10)
Novel cardiovascular magnetic resonance imaging biomarkers to track response to treatment including Sotatercept in a patient with idiopathic pulmonary arterial hypertension: a case report
Background: Pulmonary arterial hypertension (PAH) causes progressive right ventricular (RV) pressure overload and left ventricular (LV) underfilling. Sotatercept is an activin-signal inhibitor, approved by FDA in 2024 and EMA in 2025, as an add-on treatment in adult patients with PAH. Cardiovascular magnetic resonance (CMR)-derived atrioventricular plane displacement (AVPD) and left ventricular pressure–volume (PV) loops may represent non-invasive markers of treatment response, particularly important as novel therapies addressing remodelling emerge. Case summary: A 30-year-old woman was diagnosed with idiopathic PAH, after presenting with dyspnoea and peripheral oedema. Baseline CMR showed severe RV dilation, reduced RV ejection fraction, and low indexed LV stroke volume, with reduced bilateral AVPD and markedly impaired LV PV loop indices, with low stroke work, low mean external power, and high ventriculo-arterial coupling. Initial dual PAH therapy, with an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor initially improved symptoms, pulmonary vascular resistance, as well as AVPD and PV loop derived indices, whereas conventional CMR indices showed only minimal change. One year later, despite triple therapy, including prostacyclin analogue, the patient deteriorated clinically and CMR showed worsening of AVPD and PV loop indices. Treatment escalation with Sotatercept immediately improved clinical status, haemodynamic, AVPD, and PV loop indices despite persistent RV remodelling. Discussion: Serial CMR-derived AVPD and LV PV loops may provide clinically useful additional information during longitudinal follow-up of PAH patients, especially in those approaching maximal available medical therapies. In the present case, both AVPD and LV PV loops reflected treatment response, and showed significant improvement after initiation of Sotatercept.
- 30 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (10)
Open AccessNovel cardiovascular magnetic resonance imaging biomarkers to track response to treatment including Sotatercept in a patient with idiopathic pulmonary arterial hypertension: a case report
Background: Pulmonary arterial hypertension (PAH) causes progressive right ventricular (RV) pressure overload and left ventricular (LV) underfilling. Sotatercept is an activin-signal inhibitor, approved by FDA in 2024 and EMA in 2025, as an add-on treatment in adult patients with PAH. Cardiovascular magnetic resonance (CMR)-derived atrioventricular plane displacement (AVPD) and left ventricular pressure–volume (PV) loops may represent non-invasive markers of treatment response, particularly important as novel therapies addressing remodelling emerge. Case summary: A 30-year-old woman was diagnosed with idiopathic PAH, after presenting with dyspnoea and peripheral oedema. Baseline CMR showed severe RV dilation, reduced RV ejection fraction, and low indexed LV stroke volume, with reduced bilateral AVPD and markedly impaired LV PV loop indices, with low stroke work, low mean external power, and high ventriculo-arterial coupling. Initial dual PAH therapy, with an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor initially improved symptoms, pulmonary vascular resistance, as well as AVPD and PV loop derived indices, whereas conventional CMR indices showed only minimal change. One year later, despite triple therapy, including prostacyclin analogue, the patient deteriorated clinically and CMR showed worsening of AVPD and PV loop indices. Treatment escalation with Sotatercept immediately improved clinical status, haemodynamic, AVPD, and PV loop indices despite persistent RV remodelling. Discussion: Serial CMR-derived AVPD and LV PV loops may provide clinically useful additional information during longitudinal follow-up of PAH patients, especially in those approaching maximal available medical therapies. In the present case, both AVPD and LV PV loops reflected treatment response, and showed significant improvement after initiation of Sotatercept.
- 23 October 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (11) , 1683-1687
Authors’ Perspective on the International Society for Heart and Lung Transplantation Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension
- 23 October 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (11) , 1683-1687
Authors’ Perspective on the International Society for Heart and Lung Transplantation Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension
- 5 September 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (11) , e73-e131
International Society for Heart and Lung Transplantation (ISHLT) Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension
- 5 September 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (11) , e73-e131
International Society for Heart and Lung Transplantation (ISHLT) Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension
- Open Access
- 12 November 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (11) , 1787-1797
Risk assessment models and survival in pulmonary arterial hypertension: A SPAHR analysis
- 12 November 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (11) , 1787-1797
Open AccessRisk assessment models and survival in pulmonary arterial hypertension: A SPAHR analysis
- Top Cited PapersOpen Access
- 29 August 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (4) , 2401323
Risk stratification and treatment goals in pulmonary arterial hypertension
Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters (World Health Organization functional class, 6-min walk distance and natriuretic peptides) that are included in all currently validated risk stratification tools. However, suffering from limitations mainly related to reduced specificity of PAH severity, these variables may not always be adequate in isolation for guiding individualised treatment decisions. Moreover, with effective combination treatment regimens and emerging PAH therapies, markers associated with pulmonary vascular remodelling are expected to become of increasing relevance in guiding the treatment of patients with PAH. While reaching a low mortality risk, assessed with a validated risk tool, remains an important treatment goal, preliminary data suggest that invasive haemodynamics and cardiac imaging may add incremental value in guiding treatment decisions.
- 29 August 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (4) , 2401323
Top Cited PapersOpen AccessRisk stratification and treatment goals in pulmonary arterial hypertension
Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters (World Health Organization functional class, 6-min walk distance and natriuretic peptides) that are included in all currently validated risk stratification tools. However, suffering from limitations mainly related to reduced specificity of PAH severity, these variables may not always be adequate in isolation for guiding individualised treatment decisions. Moreover, with effective combination treatment regimens and emerging PAH therapies, markers associated with pulmonary vascular remodelling are expected to become of increasing relevance in guiding the treatment of patients with PAH. While reaching a low mortality risk, assessed with a validated risk tool, remains an important treatment goal, preliminary data suggest that invasive haemodynamics and cardiac imaging may add incremental value in guiding treatment decisions.
- Open Access
- 25 July 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 2 (3) , qyae128
Right ventricular stroke work index from echocardiography in patients with pulmonary arterial hypertension—the role in short-term follow-up assessment
Aims: Right ventricular (RV) failure causes high mortality in patients with pulmonary arterial hypertension (PAH). RV stroke work index (RVSWi) poses as a potential predictor of outcome. We evaluated how RVSWi by echocardiography (ECHO) or right heart catheterization (RHC) is altered following PAH treatment and if RVSWi is an indicator of outcome in PAH. Methods and results: Fifty-four patients with PAH performed ECHO and RHC (median, 0 days between examinations) at baseline and treatment follow-up. RVSWiRHC was computed as (mPAP-mRAP)×SViRHC, (mPAP, mean pulmonary arterial pressure; mRAP, mean right atrial pressure; SVi, stroke volume indexed to body surface area). ECHO-derived RVSWi was calculated as RVSWiECHO-Mean = TRmeanPG × SViECHO and RVSWiECHO-Max = TRmaxPG × SViECHO (TRmeanPG and TRmaxPG: tricuspid regurgitant mean and maximum pressure gradient). Invasive sPAP, mPAP, and pulmonary vascular resistance decreased and SVi increased from baseline to follow-up (P < 0.01 for all). RVSWiRHC and RVSWiECHO (Mean and Max) did not differ from baseline to follow-up (P > 0.05). Forty patients died during 109 ± 24 months. In univariate Cox proportional hazard analysis, age > 65 years, 6-minute-walk test < 160 m, WHO class III-IV and indexed right atrial volume were associated with long-term mortality, but none of the RVSWi methods. In multivariate analysis with clinical parameters, both RVSWiECHO methods were independently associated with mortality. Conclusion: The RVSWi methods did not differ from baseline to short-term follow-up and were not associated with long-term outcomes in univariate analysis. However, baseline RVSWiECHO was associated with mortality when adjusting for clinical parameters.
- 25 July 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 2 (3) , qyae128
Open AccessRight ventricular stroke work index from echocardiography in patients with pulmonary arterial hypertension—the role in short-term follow-up assessment
Aims: Right ventricular (RV) failure causes high mortality in patients with pulmonary arterial hypertension (PAH). RV stroke work index (RVSWi) poses as a potential predictor of outcome. We evaluated how RVSWi by echocardiography (ECHO) or right heart catheterization (RHC) is altered following PAH treatment and if RVSWi is an indicator of outcome in PAH. Methods and results: Fifty-four patients with PAH performed ECHO and RHC (median, 0 days between examinations) at baseline and treatment follow-up. RVSWiRHC was computed as (mPAP-mRAP)×SViRHC, (mPAP, mean pulmonary arterial pressure; mRAP, mean right atrial pressure; SVi, stroke volume indexed to body surface area). ECHO-derived RVSWi was calculated as RVSWiECHO-Mean = TRmeanPG × SViECHO and RVSWiECHO-Max = TRmaxPG × SViECHO (TRmeanPG and TRmaxPG: tricuspid regurgitant mean and maximum pressure gradient). Invasive sPAP, mPAP, and pulmonary vascular resistance decreased and SVi increased from baseline to follow-up (P < 0.01 for all). RVSWiRHC and RVSWiECHO (Mean and Max) did not differ from baseline to follow-up (P > 0.05). Forty patients died during 109 ± 24 months. In univariate Cox proportional hazard analysis, age > 65 years, 6-minute-walk test < 160 m, WHO class III-IV and indexed right atrial volume were associated with long-term mortality, but none of the RVSWi methods. In multivariate analysis with clinical parameters, both RVSWiECHO methods were independently associated with mortality. Conclusion: The RVSWi methods did not differ from baseline to short-term follow-up and were not associated with long-term outcomes in univariate analysis. However, baseline RVSWiECHO was associated with mortality when adjusting for clinical parameters.
- Open Access
- 20 July 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (12) , 1948-1959
Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial
- 20 July 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (12) , 1948-1959
Open AccessLong-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial
- 12 May 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (9) , 1383-1394
The impact of cardiovascular and lung comorbidities in patients with pulmonary arterial hypertension: A systematic review and meta-analysis
- 12 May 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (9) , 1383-1394
The impact of cardiovascular and lung comorbidities in patients with pulmonary arterial hypertension: A systematic review and meta-analysis
- Open Access
- 1 January 2024
- Published by Wiley in Pulmonary Circulation
- Vol. 14 (1) , e12340
Structured evaluation of unclear dyspnea–An attempt to shorten the diagnostic delay in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
- 1 January 2024
- Published by Wiley in Pulmonary Circulation
- Vol. 14 (1) , e12340
Open AccessStructured evaluation of unclear dyspnea–An attempt to shorten the diagnostic delay in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension